Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Arjun Agarwal Sells 10,000 Shares

Key Points

• Oruka Therapeutics SVP Arjun Agarwal sold 10,000 shares for about $1.05 million, reducing his holdings by 41.29% to 14,219 shares. The sale was made under a pre-arranged Rule 10b5-1 plan.
• The company reported a quarterly loss of $0.63 per share, missing analysts’ $0.60 loss estimate by $0.03.
• Analyst sentiment remains mostly positive: nine analysts rate ORKA a Buy and one a Sell, with a consensus “Moderate Buy” rating and a $141.80 price target.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $104.97, for a total value of $1,049,700.00. Following the completion of the transaction, the senior vice president owned 14,219 shares of the company's stock, valued at $1,492,568.43. The trade was a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40.
• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded up $0.36 during mid-day trading on Friday, hitting $105.35. The company had a trading volume of 679,678 shares, compared to its average volume of 1,033,539. The stock's 50 day moving average price is $89.68 and its 200-day moving average price is $72.36. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). On average, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.

Top Oruka Therapeutics Stories

These are some of the ORKA stories that stood out recently:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of the stock. Nykredit A S purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $29,000. GAMMA Investing LLC lifted its position in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company's stock worth $31,000 after buying an additional 250 shares during the last quarter. Orion Capital Management LLC purchased a new position in Oruka Therapeutics during the second quarter worth $91,000. Sterling Capital Management LLC boosted its stake in Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company's stock worth $138,000 after buying an additional 1,485 shares during the period. Finally, Natural Investments LLC purchased a new position in Oruka Therapeutics during the second quarter worth $202,000. Institutional investors own 56.44% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ORKA shares. Guggenheim restated a "buy" rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Monday, October 26th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd. BTIG Research restated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Wedbush restated an "outperform" rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $141.80.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.